Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy
Y. Kazansky, D. Cameron, H. S. Mueller, P. Demarest, N. Zaffaroni, N. Arrighetti, V. Zuco, Y. Kuwahara, R. Somwar, M. Ladanyi, R. Qu, E. De Stanchina, F. S. Dela Cruz, A. L. Kung, M. Gounder, A. Kentsis
This study identifies mechanisms of resistance to EZH2 inhibition in SMARCB1-deficient cancers and proposes combination therapies to overcome resistance.
bioRxiv · Feb 6, 2023Cancer Biology